HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 81.9%

Neg 0% Neu 81.9% Pos 0%

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.